An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Casopitant (Primary) ; Dolasetron; Granisetron; Rosiglitazone
- Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2007 New trial record.